Annexon reports Q4 2022 net loss of $34.4M; cash runway into 2025; reiterates pipeline milestones

Annexon, Inc.

Net loss of $34.4M for Q4 2022 ($141.9M full year) vs $37.4M Q4 2021.
Cash and equivalents $242.7M as of Dec 31, 2022; expected to fund operations into 2025.
R&D expenses $28.5M in Q4 2022 ($112.5M full year) vs $27.2M Q4 2021.
Phase 2 trial of ANX007 in geographic atrophy on track for initial data mid-2023.
Phase 1 MAD trial of ANX1502 initiated; proof-of-concept in CAD planned for 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Annexon, Inc. reported fourth quarter and the year ended December 31, 2022 results: net income Net loss was $34.4 million for the quarter ended December 31, 2022, and $141.9 million for the year ended December 31, 2.

Period: fourth quarter and the year ended December 31, 2022
Net income: Net loss was $34.4 million for the quarter ended December 31, 2022, and $141.9 million for the year ended December 31, 2
Result: reported results

Exact text from the filing

On March 6, 2023, Annexon, Inc. (the “Company”) announced certain financial results for the fourth quarter and the year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Annexon, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-006240

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.